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Increased survival and cell cycle progression pathways
are required for EWS/FLI1-induced malignant
transformation
Tahereh Javaheri1,2, Zahra Kazemi3,4, Jan Pencik1,3,5, Ha TT Pham1,2, Maximilian Kauer6, Rahil Noorizadeh1,2, Barbara Sax1,
Harini Nivarthi1,7, Michaela Schlederer1,3,5, Barbara Maurer1,2, Maximillian Hofbauer1, Dave NT Aryee6,8, Marc Wiedner1,7,
Eleni M Tomazou6, Malcolm Logan9, Christine Hartmann10, Jan P Tuckermann11, Lukas Kenner1,3,5,12, Mario Mikula3,13,
Helmut Dolznig3,13, Aykut Üren14, Günther H Richter15, Florian Grebien1, Heinrich Kovar6,8 and Richard Moriggl*,1,2,3
Ewing sarcoma (ES) is the second most frequent childhood bone cancer driven by the EWS/FLI1 (EF) fusion protein. Genetically
defined ES models are needed to understand how EF expression changes bone precursor cell differentiation, how ES arises and
through which mechanisms of inhibition it can be targeted. We used mesenchymal Prx1-directed conditional EF expression in
mice to study bone development and to establish a reliable sarcoma model. EF expression arrested early chondrocyte and
osteoblast differentiation due to changed signaling pathways such as hedgehog, WNT or growth factor signaling. Mesenchymal
stem cells (MSCs) expressing EF showed high self-renewal capacity and maintained an undifferentiated state despite high
apoptosis. Blocking apoptosis through enforced BCL2 family member expression in MSCs promoted efficient and rapid sarcoma
formation when transplanted to immunocompromised mice. Mechanistically, high BCL2 family member and CDK4, but low P53 and
INK4A protein expression synergized in Ewing-like sarcoma development. Functionally, knockdown of Mcl1 or Cdk4 or their
combined pharmacologic inhibition resulted in growth arrest and apoptosis in both established human ES cell lines and EF-
transformed mouse MSCs. Combinatorial targeting of survival and cell cycle progression pathways could counteract this
aggressive childhood cancer.
Cell Death and Disease (2016) 7, e2419; doi:10.1038/cddis.2016.268; published online 13 October 2016
Ewing sarcoma (ES) is a highly metastastatic bone and soft
tissue tumor with poor survival rates. The malignancy is
caused by fusion of chromosome 11 and 22 creating the
EWS/FLI1 (EF) transcription factor. EFexpression is important
for ES maintenance and compounds targeting EF protein
are being developed for clinical applications.1–4 To study EF
expression with a mouse model that faithfully resembles ES
development remains difficult owing to high toxicity induced
by EF. It is controversial if EF expression alone is sufficient
to promote ES or if it requires cooperating mutations.
Despite EF-induced toxicity, murine or human mesenchymal
stem cells (MSCs) tolerate expression, but only murine
EF-transduced MSC displayed sarcoma formation upon
transplantation in immunocompromised mice.5–8 One lenti-
viral overexpression approach identified ERG-expressing
embryonic superficial zone cells from murine cartilage as
sarcoma stem cell origin.7 Tumor formation was influenced by
positional effects of lentiviral vector integration into cancer-
associated gene loci, but a unified hotspot integration was not
reported.7 Zebra fish-mediated EF or endogenous EWSR1- or
Rosa26-promoter-driven EF expression in mice promoted
high apoptosis induction preventing ES.9–11 Although high EF
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expression caused embryonic lethality, moderate EF expres-
sion in two transgenic founder lines was associated with mild,
but consistent limb shortening with normal life span without
ES appearance. Compound cross with p53-deficient mice
(Prx1Cre-mediated p53 deletion) synergized in osteosarcoma
formation.12,13 Furthermore, data from six independent
laboratories presented 16 different Cre-mediated transgenic
approaches to generate an Ewing Sarcoma mouse, which
failed owing to high apoptosis and toxicity upon EF expression
in multiple cell types.14
We aimed to better model the cellular origin of ES and we
used Prx1Cre (EFPrx1) mice, which facilitated EF expression
to early mesenchymal progenitors. EF expression caused a
bone differentiation arrest owing to changed developmental
signaling. As a result, severe malformations of the skull, facial
bones, sternum and limbs and early perinatal death occurred.
EF-immortalized MSC-like cells isolated from EFPrx1 limbs
displayed high levels of apoptosis but failed to form ES.
However, when cells were transduced by retrovirus to express
BCL2 family members, they formed efficiently sarcomas in
NSG mice. Sarcomagenesis was accompanied by upregula-
tion of the CDK4/cyclin D1/pRB axis, and reduced INK4A and
P53 expression accelerating cell cycle and survival. Depletion
of Mcl1 or Cdk4 in a panel of EF-dependent cell lines led to
inhibition of cell proliferation and enhanced apoptosis.
Combined blockade of MCL1 and CDK4 with pharmacologic
inhibitors caused cell cycle arrest and apoptosis in EF-
transformed cells.
Results
Skeletal defects in EFPrx1 mice are due to blocked bone
differentiation. We limited EF expression to early mesench-
ymal progenitors using Prx1Cre (EFPrx1) to better model the
cellular origin of ES. To regulate EF expression in target
tissues we used an EF expression cassette flanked by a
floxed STOP cassette knocked into the Rosa26 locus.10
Compound mice with conditional mesenchymal Prx1Cre
recombinase expression (Figure 1a) were generated.
Prx1Cre-mediated recombination was reported from E9.5
onwards in bone-forming cells.13 Prx1 promoter-driven EF
expression was shown to be tolerated, which resulted in
shortened limbs upon transgenic expression, but detailed
bone development was not analyzed.12 Here, we aimed to
express EF during early development, as cases of congenital
ES in newborns exist.15,16 EF expression caused develop-
mental abnormalities such as endochondral bone formation
arrest, starting at E10.5 up to postnatal day P1 (Figure 1). EF-
expressing embryos or newborns displayed gross malforma-
tions in limb development that became apparent at E12.5.
The phenotype was more prominent from anterior-to poster-
ior and at later developmental stages (Figure 1b; Supple-
mentary Figure 1a–c). Malformations in rib cage architecture
and in the craniofacial area most likely led to death of EFPrx1
newborn mice within the first 24 h postnatal owing to breath-
ing and nutrition problems. Spine development remained
normal (Supplementary Figure 1d). Alcian Blue/Alizarin Red
staining, which stains cartilage in blue and bone elements
in red, and skeletal analysis displayed severe reduction in
calcified deposition (red elements) of long bones in EFPrx1
versus wild-type (wt) limb bones at E16.5. Furthermore, we
observed a distorted sternum with deranged ossification
center, causing an open, malformed rib cage. Calvaria bones
lacked significant calcification, leading to skull malformations
(Figure 1b). Mutant mice were born at normal Mendelian
ratios (n=174 EFPrx1 versus n= 161 wt controls were
analyzed; Figure 1c). Detailed histological analysis of E13.5
and E18.5 embryos revealed two different phenotypes in
limbs. All mutant embryos analyzed showed condensed
cartilaginous elements instead of long bone formation.
Although ~90% of mutants displayed polydactyly, only
~ 10% EF embryos lacked digits or long bone elements
(Figure 1d; Supplementary Figure 1e). Van Kossa/Alcian
Blue staining of E13.5 and E18.5 embryos revealed blocked
mesenchymal differentiation in EFPrx1 mice at the pre-
hypertrophic chondrocyte stage. In line, all mutant embryos
showed absence of hypertrophic and mature chondrocytes or
osteoblasts as confirmed by RNA in situ hybridization for
bone lineage markers. Interestingly, although early markers
of the chondrocyte lineage (Sox9, Collagen 2a1, Col2a1)
were expressed in EFPrx1 limbs, markers of hypertrophic
chondrocytes and osteoblast differentiation (Indian hedge-
hog, Ihh; Collagen10, Col10a1; Runt-related transcription
factor 2, Runx2 and Osterix, Osx) were largely absent in long
bone areas, but weakly expressed in polydactyly digits. In
rare cases, EF embryos lacked both digits and limbs, best
visible by condensed Collagen 2a1-expressing cartilage
elements at late development (Figure 1d; Supplementary
Figure 3a). Similarly, osteoblast markers Col1a1 and Osc
were absent in limbs isolated from EFPrx1 embryos, but
expressed in wt limbs (not shown). Immunoblotting analysis
confirmed significant EF expression in limb elements
(Figure 1e). Efficient deletion of the STOP cassette and
expression of EF was confirmed by genomic or real-time
PCR (Supplementary Figure 2).
Figure 1 EF expression blocks bone differentiation causing skeletal defects in EFPrx1 mice. (a) Scheme of the ROSA26-lox-STOP-lox-HA-hEWS/FLI1 transgenic mouse.
(b) Representative picture of wt and EFPrx1 E16.5 embryo displays malformed limbs as indicated by black dashed circle. Skeletal preparations and analysis with Alcian Blue/
Alizarin Red staining of E16.5 wt and EFPrx1. sc, scapula; hu, humerus; ra, radius; ul, ulna; ti, tibia; fi, fibula; fe, femur. (c) The list summarizes number of embryos (total, wt, EFPrx1)
at different gestation days, and cumulative percentages/normal Mendelian ratio with indicated embryo numbers. (d) Histology analysis of E13.5 limbs stained by H&E or Van
Kossa/Alcian Blue, which stains cartilage in blue and bone elements in red, indicated that there was no significant hypertrophic region present in EFPrx1 embryos in contrast to wt
limbs. RNA in situ hybridization of E13.5 limbs confirmed an arrest in chondrocyte and osteoblast differentiation. For all embryos consecutive sections were performed. At least
three different independent embryos for every single staining and for each time point were analyzed. Black circles indicate the magnified region showing in the lower row.
(e) Detection of EF expression at the protein level at E16.5 using HA-tag antibody displayed significant transgenic protein product in limbs from EF mice. HSC-70 was used as a
loading control. Fibro GFP or CRE: fibroblasts isolated from EF mice lentiviral-transduced with a construct containing GFP or the CRE recombinase was used as controls.
Numbers of analyzed embryo/mice are indicated to corresponding images
Inhibition of apoptosis promotes Ewing sarcoma
T Javaheri et al
2
Cell Death and Disease
Impairment of bone development pathways in EFPrx1
limbs. EF+ embryos at different embryonic stages (E14.5,
E16.5 and P1) showed a severe reduction of mature chondro-
cytes in mutant limbs, as measured by dimethylmethylene
blue staining, which reflects sulphated glycosaminglycane
content (Figure 2a; Supplementary Figure 3b). The WNT/
β-catenin pathway has a pivotal role in chondrocyte and
osteoblast differentiation in cooperation with BMP/SMAD and
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TGF-β signaling.17–22 We analyzed by immunostaining key
marker proteins (β-CATENIN, SMAD1/5, pSMAD4, SMAD7,
DLX5, SOX9, RUNX2 and OSTERIX) along bone differentia-
tion markers. Automated quantification of immunostaining
served as reliable source to quantify levels.23 RUNX2,
OSTERIX, DLX5, pSMAD4, SMAD1/5, SMAD7 and
β-CATENIN were found diminished at all embryonic stages
in EFPrx1 transgenic limbs (Figures 2a and b; Supplementary
Figure 2 Blocked bone signaling pathways upon EF expression. (a and b) Dimethylmethylene blue (DMMB) as a chondrocyte marker showed marked reduction of
Glycosaminoglycan in mutant embryos. IHC staining analysis on consecutive embryo sections of E14.5 and postnatal day P1 mice showed that EF expression in limb
mesenchyme promotes downregulation of TGF-β signaling pathway. Black circles indicating the magnified region showing in the next column. (b) Quantification of IHC signals
from (a). At least three different independent embryos for every single staining and for each time point were carried out. Quantitation was done by (ANOVA) one-way analysis of
variance. *Po0.5, **Po0.05 and ***Po0.005
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Figure 4), whereas SMAD7 expression at birth was compar-
able with wt expression levels. SOX9 expression for pre-
hypertrophic chondrocyte differentiation, controlling secretion
of extracellular matrix molecules like collagen and proteo-
glycans24 was normal during early development. DLX5 as a
TGF-β-induced protein was downregulated in mutant limbs
compared with controls (Figures 2a and b; Supplementary
Figure 4).
Figure 3 EF expression induces apoptosis and leads to diminished cell cycle progression. (a) HA-tag staining was performed to detect the EF translocation product. The rate
of proliferation was comparable to wt based on Ki67 proliferation marker staining. TUNEL staining displayed highly elevated apoptosis at P1. (b) P21 (CDKN1A) protein level was
upregulated. Prominent nuclear staining of P21 at E14.5, decreased at E16.5 and P1. cyclin D1 expression was decreased during development till P1. Black circles indicating the
magnified region showing in the next column. (c) Quantification of IHC from part A and B. At least three different independent embryos of wt or mutant for every single staining and
for each time point were analyzed. Experimental staining results were evaluated using (ANOVA) one-way analysis of variance. Insets in separate panel highlight cellular details.
*Po0.5, **Po0.05 and ***Po0.005
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High level of apoptosis in limb elements of EF-express-
ing newborns. Next, we investigated EF expression and
highest expression was seen at E14.5 and E16.5, whereas its
expression diminished at P1 (Figures 3a–c; Supplementary
Figure 5). The proliferation rate of EF-mutant chondrocytes
was not significantly changed, as measured by Ki67 staining.
However, TUNEL staining showed marked rates of apop-
tosis at P1 in mutant but not wt limbs (Figures 3a–c;
Supplementary Figure 5). Of note, nuclear P21 (CDKN1A),
a known senescence marker often lost or mutated in human
cancer25 was induced at E14.5, but suppressed from E16.5
on in EF-mutant limbs. Moreover, cyclin D1 expression was
slightly decreased throughout development of EFPrx1 trans-
genic limbs, whereas its expression was diminished at birth
(Figures 3a–c; Supplementary Figure 5).
EF-expressing MSCs are immortal and fail to differenti-
ate. To study primary cells of malformed bone elements, 12
different primary EFPrx1MSC-like cell cultures (MSCL) from
individual P1 EFPrx1 (EFPrx1MSCL) or six wt limbs (wtMSCL)
as controls were propagated (Figure 4a; Supplementary
Figure 6a–c). We applied specific differentiation protocols
for osteoblasts, chondrocytes or adipocytes. WtMSCL cells
displayed prominent differentiation into all three lineages, but
EFPrx1MSCL reproducibly failed to differentiate (Figure 4a).
Transgene expression of EF at the RNA- and protein level in
EFPrx1MSCL cultures was verified and cells expressed CD90
(Thy-1.1) as a MSC marker (Figure 4b). Furthermore, mRNA
expression for TGF-β receptor chains (TgfbrI or TgfbrII) and
bone differentiation markers Ostx, Sox9, Runx2, Osc and
Dlx5 as the osteoblast differentiation master regulator was
decreased in EFPrx1MSCL, whereas expression of hedgehog
signaling components Gli1, Ihh and Smo was elevated. P53
and c-myc were comparable to controls (Figure 4c; Supple-
mentary Figure 6d; P53 protein level was also similar, not
shown). WtMSCL displayed growth arrest after ~ 6–8
passages with senescence-like features such as PML+
immunostaining (not shown). In contrast, mutant EF+MSCL
were continuously passaged (450 passages). We did not
observe senescence in EFPrx1MSCL and cells remained
diploid even at passage 55. Cell cycle analysis of multiple
different primary EFPrx1MSCL lines at early and late passage
numbers (passage 8 and 55) displayed a large fraction
(440%) of cells at sub-G1 at early passage, but high rate of
apoptosis was lost at late passage. Apoptosis loss was
associated with a higher number of cells that remained in
G2/M phase compared with wtMSCL (Figure 4d). High level
of apoptosis in EFPrx1MSCL cells correlated with high
Caspase-3 mRNA levels (Figure 4d) paralleled by 480%
TUNEL+ cells in limb elements at P1 of EFPrx1 newborns.
Enforced BCL2 family member expression promotes
sarcoma formation. We suspected that BCL2 family mem-
ber expression in ES could be high. Indeed, all three family
members, MCL1, BCL2 and BCL-xL in ES cell lines SK-N-
MC, TC71, TC252 and A673 were prominently expressed by
Western blot analysis. Levels of protein expression were
comparable to colorectal cancer cell lines HT29, HCT116,
SW620 and LS174T, which are known to rely on high BCL2
family member expression to maintain viability.26 We also
checked CDK4 expression in ES cell lines as a proliferation
marker, which was upregulated compared with control cells
(human prostate epithelial RWPE-1 cells; Figure 5a).
EFPrx1MSCL were unable to promote sarcomagenesis when
4× 106 cells embedded in matrigel were s.c. injected into
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) recipients. We
kept EFPrx1MSCL continuously in culture for more than 1
year and despite high passage number (455 passage),
we failed to detect tumourigenesis in NSG mice (Figure 5b).
We conclude that primary EFPrx1MSCL cell lines are immortal
and differentiation-resistant, but incapable to initiate sarco-
mas. BCL2 family members are proto-oncogenes and they
promote survival and facilitate proliferation of cancer cells.27
Therefore, we examined if exogenous provision with Bcl2,
Bcl-xL or Mcl1 could promote sarcomagenesis. We trans-
duced Bcl2, Bcl-xL and Mcl1 by retroviral means (Bcl2-IRES-
eGFP, Bcl-xL-IRES-eGFP, Mcl1-IRES-eGFP or GFP-vector
control) in primary EFPrx1MSCL or wtMSCL lines to test their
transforming capability. All transduced EFPrx1MSCL cell lines
with BCL2 family members gave rise to prominent sarcoma
formation within 3–4 weeks and with 100% penetrance when
4× 106 Bcl2-, Bcl-xL- or Mcl1-transduced EF
Prx1MSCL cells
were injected. WtMSCL with or without BCL2 family member
transduction or GFP-vector transduced EFPrx1MSCL cells did
not form any tumor. All transplanted cells were embedded
in matrigel to enhance engrafting and NSG mice of control
groups were followed up to 6 months. Consistently, high
tumor burden and growth rate was found with any of the
BCL2-transduced EFPrx1MSCL (Figure 5b; Supplementary
Figure 7a and b). Remarkably, EFPrx1MSCL+Bcl2 cells
were more invasive with higher tumor weight, whereas
EFPrx1MSCL+Mcl1 cells expanded along the skin and
muscle areas (Supplementary Figure 7a). Histo-pathology
analysis of sarcoma sections confirmed a Ewing-like
Figure 4 EFPrx1 mesenchymal stem cells like cells (EFPrx1MSCL) are immortal, but display high apoptosis and fail to differentiate. (a) MSCL were isolated from P1 mouse
long bone cartilaginous elements of wt or EFPrx1 newborns (left). A representative primary cell line from low passage 3–4 in case of wtMSCL or passage 8–10 in case of
EFPrx1MSCL line is shown. WtMSCL were able to differentiate along mesenchymal lineages, whereas EFPrx1MSCL failed to differentiate. Differentiation was induced as detailed in
Materials and Methods to obtain osteocytes (stained with Alizarin red), chondrocytes (Van Kossa staining) and adipocytes (Oil red O staining). An example from three
independent differentiation experiments is shown (right). (b) Western blot analysis (n= 2, each) of HA-tag and qRT-PCR (n= 6, each) proved significant EF transgene
expression. The EFPrx1MSCL displayed high surface expression of CD90 (Thy-1.1; n= 3, each), a MSC marker, compared with wtMSCL. (c) EFPrx1MSCL has blunted TGF-β
signaling as measured by reduced expression levels of TgfbrI, TgfbrII and Dlx5. Similarly, osteogenic markers like Osx, Sox9 and Osc were expressed to lower levels, but
enhanced hedgehog signaling was found as evident by higher Ihh, Smo andGli1 expression using qRT-PCR. Error bars represent S.E.M. of six individual measurements. All qRT-
PCR results were normalized to Gapdh. For wt or mutant embryos at least three different independent experiments were carried out. (d) Representative cell cycle analysis of six
wtMSCL (passage 3) or 12 EFPrx1MSCL at early (passage 8) or late (passage 55) culture time as measured by propidium iodide (PI) staining. Caspase-3 expression was induced
in EFPrx1MSCL as measured by qRT-PCR compared with wtMSCL levels causing high apoptosis. *Po0.5, **Po0.05 and ***Po0.005
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sarcoma morphology (Figure 5c; Supplementary Figure 7c).
All sarcomas showed uniform small blue round cells with
prominent nucleoli surrounded by small cytoplasm. Next
we tested sarcoma cells for two established ES markers:
periodic acid schiff (PAS) and neuronal-specific enolase
(NSE) immunostaining confirmed ES-like staining pattern
(Figure 5c; Supplementary Figure 7c).
MCL1 transduction resembles a close human ES gene
expression profile. To determine the similarity in gene
expression of the transplant model with human ES we
performed RNA-seq analysis. Data were compared with a
published ES signature (Kauer data set).28 A more optimal
gene expression profile for EFPrx1MSCL+Mcl1 sarcomas
was prominent, when comparing relative expression
levels of these signature genes in wtMSCL, EFPrx1MSCL,
EFPrx1MSCL+Bcl2, EFPrx1MSCL+Mcl1 (Figures 5d and e) or
EFPrx1MSCL+Bcl-xL (data not shown) to human data. This
suggests that transformation with MCL1 renders EFPrx1MSCL
more similar to ES. We next examined whether on a
transcriptomic level ES correlates better with the EFPrx1MSCL
+Mcl1 transplant model than other human sarcomas using a
comprehensive set of microarray data for different human
sarcomas.29 From this data set normalized gene expression for
each sarcoma was correlated with the log2 fold change of
EFPrx1MSCL+Mcl1 versus wtMSCL. Although overall correla-
tions to other sarcomas were low, the highest positive correla-
tion (red bars) was seen for ES. This result suggests that among
the tested sarcomas gene expression changes in the
EFPrx1MSCL+Mcl1 as compared with wtMSCL is overall most
similar to ES (Figure 5e). To determine functional categories of
gene regulation we performed gene set enrichment analysis.
Most prominently, we found different gene sets relating to cell
cycle to be enriched in genes upregulated in the comparison
EFPrx1MSCL+Mcl1 versus wtMSCL cells (Figure 5f), whereas
the p53 signaling pathway was downregulated.
Tunnel and PI staining showed less tunnel-positive cells and
more proliferation rate in EFPrx1MSCL+Mcl1 cell population,
indicating the crucial role of Mcl1 for bypassing apoptosis in
EF-expressing cells (Figure 5g; Supplementary Figure 7d).
We noted similar amounts of immunostainig for key markers
such as CC-3, Ki67, β-CATENIN, CYCLIN D1, CDK4/6
expression (Supplementary Figure 7g) in the compared
groups upon quantification of the IHC as shown in Figure 5h.
Western blot analysis displayed in average among 8 EFPrx1
MSCL+Mcl1 tumors compared with two EFPrx1MSCL+Mcl1 or
two EFPrx1MSCL expressing cells similar protein levels of
CC-3 and reduced INK4A or P53 levels as quantified by
densitometry (Supplementary Figure 7h). RB expression was
lower, but pS780-RB expression was higher and CDK6
expression was also higher. Furthermore, sarcoma cells
isolated from EFPrx1MSCL+Mcl1 tumors and recultivated
displayed changed expression, most notable for upregulated
p53, MCL1 and CDK6 expression. Interestingly, we observed
a severe reduction of P19ARF and P53 expression in the
majority of eight analyzed tumors of the EFPrx1MSCL+Mcl1
group, whereas P19ARF expression was lower in six tumors.
In line, we also found a significant reduction of P16Ink4A
in both EFPrx1MSCL+Mcl1 cell lines and in the majority of
EFPrx1MSCL+Mcl1 tumors. P19ARF and P16Ink4A were
expressed lower in EFPrx1MSCL+Mcl1 tumor-derived cells
and P53 expression was significantly enhanced in EFPrx1
MSCL or even expressed/activated higher upon MCL1
transduction before transplant (Figure 5h). Total RB expres-
sion levels were slightly reduced (Supplementary Figure 7e).
Blocked survival and proliferation arrests ES cell growth
and induces apoptosis. CDK4 activity is required for cell
cycle progression and it was shown that Mcl1 knockdown
prolonged early G1 phase associated with decreased CDK4
expression.30,31 Upon siRNA-mediated knockdown of Mcl1
or Cdk4 in Ewing-like mouse as well as in ES cell lines TC252
and SK-N-MC we could demonstrate that both genes are
important for ES cell growth and survival (Figure 6).
Mechanistically, we observed a slightly lower expression of
pS780-RB after downregulation of Mcl1 or Cdk4, whereas
total RB levels were increased, indicating that Mcl1 and Cdk4
downregulation resulted in blocked proliferation (Figure 6a,
Supplementary Figure 7i). Tumorigenic potential of siRNA-
treated cells was assessed by colony-forming assay. The
amount of Mcl1 or Cdk4 correlated with the number of
colonies, indicating that MCL1 and CDK4 are required for
efficient transformation. A siRNA-positive control targeting EF
in EFPrx1MSCL+Mcl1 cells confirmed proliferation was EF-
dependent (Figures 6a and b). Cell cycle analysis revealed
that less Mcl1 or Cdk4 led to a prolonged G0/G1 and
Figure 5 EFPrx1MSCL give rise to sarcomas upon enhanced expression of anti-apoptotic BCL2 family members. (a) ES cell lines SK-N-MC, TC71, TC252 and A673
expressed prominent level of MCL1, BCL2 and BCL-xL. Colorectal carcinoma cell lines HT29, HCT116, SW620 and LS174Twere used as positive control. CDK4 expression was
higher than in the control human prostate epithelial cell line RWPE-1. (b) Four different EFPrx1MSCL and four different wtMSCL were transduced by retrovirus with either GFP-
vector, Bcl2-IRES-eGFP, Bcl-xL-IRES-eGFP or Mcl1-IRES-eGFP. A total of 12 primary cell transductions for each cell line were xenografted (n= 12, each). All Bcl2, Bcl-xL and
Mcl1-expressing EFPrx1MSCL lines formed reproducibly sarcomas with full penetration as quantified in the right graph. None of the controls like the wtMSCL with or without BCL2
family member transduction or GFP-transduced EFPrx1MSCL formed any sarcoma up to 6 months post transplant. (c) Xenografted sarcomas were positive for periodic acid schiff
(PAS) and neuronal-specific enolase (NSE) staining. SK-N-MC xenograft served as positive control. (d) RNA-seq analysis (from left to right) of wtMSCL, EFPrx1MSCL, two
sarcoma samples from EFPrx1MSCL+Bcl2 and EFPrx1MSCL+Mcl1 revealed that samples become more similar to the ES gene expression signature (Kauer data set28).
(e) Clustering analysis showed the best matching of EFPrx1MSCL+Mcl1 tumor genes to human ES signatures. (f) Gene enrichment analysis (GSEA) exhibited a noticeable
upregulation of cell cycle and a downregulation of p53 pathway in mouse EFPrx1MSCL+Mcl1 tumors versus wtMSCL. (g) EFPrx1MSCL at passage 30 served as controls. Two
representative sarcoma lines EFPrx1MSCL+Mcl1 were established each that displayed an increase of GFP expression and a decrease in TUNEL+ cells after sarcomas formed,
whereas PI staining displayed more proliferation in EFPrx1MSCL+Mcl1 and EFPrx1MSCL+Mcl1 tumor-derived cells. (h) Proliferative sarcoma cells were also positive for nuclear β-
catenin, cyclin D1, CDK6 and CDK4, whereas cleaved caspase-3 (CC-3) was downregulated. All shown staining images are a representative of independent IHC analyses of
n= 12 isolated tumors per group. (i) Western blot of two EFPrx1MSCL, two EFPrx1MSCL+Mcl1, eight EFPrx1MSCL+Mcl1 sarcomas and two EFPrx1MSCL+Mcl1 tumor-derived cells
showed an overall reduced level of caspase-3 (Pro CC-3), CC-3, P16Ink4A, P19ARF, P53 and higher amount of pS780-RB protein level upon enforced MCL1 expression in
EFPrx1MSCL and associated tumor samples. Representative blots of three independent analyses are shown
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shortened S and G2/M phases (Figure 6c). To evaluate
results of siRNA-mediated downregulation of Cdk4 and to
translate findings to pharmacologic targeting, we treated
EF-dependent cells with Palbociclib, an FDA approved dual
CDK4/6 inhibitor. Palbociclib (IC50=~1 μM in human ES cell
lines and IC50=~2 μM in mouse EF-dependent cell lines)
p-value: 0.01
FDR: 0.710
p-value: 0.0   
FDR: 0.004
Enrichment plot: p53 pathway
59 genes
Enrichment plot: cell cycle process
162 genes
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exposure led to reduced pS780-RB and increased total RB,
whereas MCL1 levels were slightly decreased. Only a
combination of CDK4/6 with the pan BCL2 family inhibitor
Obatoclax resulted in significant growth inhibition of ES cells,
whereas a BCL2 family inhibitor unable to target MCL1
(ABT-737) was inefficient to block proliferation (Figures 6d
and e; Supplementary Figure 7j). Western blot analysis of
treated human cell lines with Obatoclax and ABT-737 showed
higher CC-3 intensity in cells treated with Obatoclax. The ES
cell line T252 showed higher expression of CC-3 after
treatment with ABT-737 (Supplementary Figure 8b).
Discussion
Childhood cancer studies are greatly hampered by small study
cohorts32 and an animal model to study ES is needed for
Figure 6 Knockdown of Mcl1 or Cdk4 induced cell cycle arrest and inhibited ES cell proliferation. (a) Mcl1 and Cdk4 siRNA analysis and expression check in murine and
human ES cell lines resulted in upregulation of total RB and lower amount of pS780-RB. (b) Colony-forming assay in matrigel displayed reduced clonogenic potency of EF-
dependent cell lines after knockdown of Mcl1 or Cdk4 by siRNA treatment. (c) Cell cycle analysis of Mcl1 or Cdk4 siRNA treatment displayed enhanced G1 arrest. (d) In vitro
growth inhibition of mouse and human EF-dependent cell lines by Palbociclib as well as the combinatorial treatment of Palbociclib and Obatoclax in triplicate. Cells were treated
with inhibitors at the indicated concentration for 24 h. (e) CDK4/6 inhibition by Palbociclib displayed similar results as seen in the CDK4 siRNA assay
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preclinical drug testing and mechanistic insights into disease
processes. We aimed to better model the cellular origin of ES
through the use of Prx1Cre-driven EF expression. Moreover, we
developed new primary cell models to study EF expression
consequences on core cancer pathways such as apoptosis and
cell cycle progression or bone developmental signaling
pathways.25–27,33–35 We conclude that EF expression blocks
mesenchymal differentiation and it induces apoptosis. This cell
death in the developing mesenchyme caused severe malforma-
tions in bonedevelopmentwith death in newborn owing to severe
bone differentiation abnormalities, making a transplant model
necessary. Therefore, we established a new in vivo transplant
system to serve for drug testing studies and for mechanistic
insights into key pathways driving sarcomagenesis.
ES cases in babies were reported15,16 and therefore, our
transgenic EF expression during limb differentiation could
illuminate sarcoma formation in patients. We established
multiple primary cell lines that were transformed to form
sarcomas in vivo upon enforced BCL2 family member
expression. We illuminated sarcoma formation through
analysis and quantitation of key proteins involved in cancer
progression. We found that our genetically engineered mouse
model resembled sarcomas with close ES gene expression
profile28 as determined by RNA-seq analysis, which could be
useful to search for therapeutic intervention strategies. We
found upregulated MCL1, CYCLIN D1, CDK4, but down-
regulated INK4A or P53 protein levels as prerequisites for ES
proliferation and survival in line with similar findings in ES
patients.36,37
We observed an anterior-to-posterior differentiation defect,
which could follow the wave of MSC dissemination in
mammals that originate from neural crest. We noted deregu-
latedWNT; HEDGEHOG, BMPand TGF-β pathways17–21 that
culminated into skeletal development defects. Polydactyly was
associated with elevated hedgehog signaling and Gli1
expression known to be EF-dependent.38 Analysis of chon-
drogenesis and osteogenesis markers revealed an arrest of
endochondral bone development. Inhibition of Runx2, TgfbrI
or TgfbrII could be due to reported repression by EF.39,40
Consequently, mature osteoblast markers lacked and TGF-β/
BMP signaling was diminished. Normally, cartilage-derived
β-catenin signaling promotes chondrocyte maturation and it is
involved in ossification. BMPand TGF-β signaling are required
for osteoblast and chondrocyte differentiation,17,20,21,41 but
bone invasion and osteolysis in ES are also associated with
enhanced β-catenin signaling.42,43 We observed downregu-
lated BMP, TGF-β and β-catenin signaling at late development
in EFPrx1 embryos, but high β-CATENIN expression was seen
when sarcomas formed.
EFPrx1MSCL remained diploid despite high passages,
but transformation did not occur. Interestingly, EFPrx1MSCL
were immortal, but wtMSCL underwent senescence at low
passage. Furthermore, despite contradictory literature,
EFPrx1MSCL failed to differentiate, whereas wtMSCL differen-
tiated normal.5–8 EF-induced apoptosis was prominent in line
with literature that identified Procaspase 3 to be a direct target
gene of EF.11 Higher expression of CASPASE-3 could be seen
in liver and spleen of transgenic mice expressing EF.10
Introduction of EF in human mesenchymal progenitor can
also induce prominently apoptosis.44
Enforced BCL2 family member expression was efficient
to promote sarcomagenesis of transplanted EFPrx1MSCL.
MCL1 resulted in highest similarity of tumor gene expression
to human ES. Although survival is a core cancer pathway,
the high protein expression of BCL2 family members in ES
was so far neglected. Currently, we cannot rule out that a
possible post-translation mechanism for high BCL2 family
member protein expression could be responsible during
Ewing sarcomagenesis. We conclude that overcoming high
CASPASE-3-induced apoptosis will be important for transfor-
mation. Similarly, cell cycle deregulation in ES is also a
consequence of transformation. A direct correlation between
EF expression and the amount of cyclin D1 expression was
shown33,34,45 and c-myc upregulation correlates with the Ki67
proliferation marker expression.46 We observed low expres-
sion of INK4A and/or P53 proteins in the majority of
transplanted tumors from the MCL1 or BCL2 expressing
cohort. Collectively, these results indicate a significant ES
selection pressure for escape of apoptosis. Low expression of
CDKN2A and/or P53 correlates with decreased apoptosis, or
in case of CDKN2A loss also with enhanced self-renewal
capacity of MSC.36 INK4A proteins are frequently lost owing to
homozygous deletion or p53 mutations, both prominent in
patients with ES.37,47 Enhanced survival in collaboration with
decreased pS780-RB expression and increased CDK4 l
evels could also boost transformation. It was shown that
MCL1 and cell cycle progression are interconnected andmore
MCL1 expression accelerated the cancer cell cycle
progression.30,31 Here, we found that MCL1 knockdown led
to a G1 cell cycle arrest by decreasing CYCLIN D1, CDK4/6
and by increasing P27 expression.30,31 Enforced survival led
to increased CDK4 expression and pRB phosphorylation.
Knockdown of Cdk4 or Mcl1 in a panel of EF-dependent
cell lines led to inhibition of cell proliferation and reduced
colony formation. Targeting BCL2 family members display
ed higher efficacy with Obatoclax versus ABT-737 treatment,
but combination of Obatoclax with Palbociclib was most
effective. Our findings extend and confirm also recent
results that describe the requirement of ES cells for CYCLIN
D1-CDK4/6 function.35
In summary, our findings propose that enhanced survival
and proliferation with blocked mesenchymal differentiation are
three prerequisites for Ewing Sarcoma formation. Our study
displays mechanistic insights how the high apoptosis induced
through EF-induced Caspase-3 mRNA and protein expres-
sion can be overcome to promote sarcomas. We could show
that pharmacologic inhibitors of CDK4/6 and BCL2 family
members are more effective when combined as targeted
inhibitors. Thus, new targeting approaches could be tried to
counteract this metastasizing disease in a more efficient way.
Materials and Methods
Animal models and ethical approval. Transgenic Rosa26-EF10 were
crossed to Prx1Cre mice.13 To isolate embryos vaginal plug checks were made,
mice were separated and noon was counted as E0.5. Mice were kept under SBF
conditions and animal experiments were approved (license number: BMWF-66009-
/0281-I/3b/2012). Immunocompromised NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)
recipients were purchased (Harlan, United Kingdom).
Cell culture, gene knockdown assay and inhibitor treatment.
Cells were cultivated for inhibitor Palbociclib (PD-0332991) HCl in a dose–response
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cellular viability assay, incubated for 24 h (Selleckchem, Houston, TX, USA) with
doses: 0, 0.3, 0.5, 1, 2, 5 and 7 μM followed by viability counting using trypan blue.
For inhibitor treatment viability values, IC50 was determined for human at 1 and for
murine tumor cell lines up to 2 μM. Treated cells were harvested for Western blot
after 24 h treatment. For time-course assays, cells were seeded in tissue culture
with inhibitors or vehicle (DMSO) up to 3 or 4 days. Ontarget Plus pool siRNAs
for each individual gene were purchased and transfected as instructed (GE
Dharmacon, Lafayette, CO, USA).
In situ hybridization. Digoxigenin-labeled cRNA probes were generated by
in vitro transcription of 1 μg template DNA with RNA DIG labeling kit (Roche
Diagnostics GmbH, Mannheim, Germany) according to manufacturer. In situ
hybridizations were performed on serial paraffin sections as described.48 For each
probe and time point, embryo sections were located for staining on one slide to
allow for comparison.
Quantitative immunostaining. Four precent formalin-fixed embryos were
embedded in paraffin. Sections were processed prior to staining with specific
antibodies (see Supplementary Table S2). Quantification of stained embryos was
performed with one-way Anova test23 with Histo Quest analysis software (Tissue
Gnostics GmbH, Vienna, Austria).
Bioinformatic analysis. Illumina kits for strand-specific library preparation
was used for RNA-seq and RNA was quantified using Qubit 2.0 Fluorometric
Quantitation system (Life Technologies, Waltham, MA, USA). For comparison with
human expression data orthologs were mapped using the biomaRt package
(PMID:19617889). Gene set enrichment analysis was performed with java
command line program (gsea2-2.0.13.jar) using the ‘preranked’ method from the
BROAD institute (PMID:16199517) and gene sets from MSigDb (http://software.
broadinstitute.org/gsea/msigdb). Heatmap in Figure 5d: Mouse orthologs for genes
in gene signature from28 were selected. Row-wise scaled, mean normalized
expression levels for the four sample groups are shown. Genes in the heatmap are
ordered by expression difference (ES tumor versus MSC) of human orthologs. Blue
color indicates genes with lower expression in ES than in MSC, whereas red shows
genes with higher expression in ES than in MSC. Correlation analysis: Sarcoma
data from ref. 29 were filtered by excluding probe sets that had missing values in
more than samples. Then for each gene the most variable probe set was selected
and averaged per sarcoma entity.
Statistical analysis. All results are presented as means± S.E.M. Data were
considered statistically significant as described in each panel. All analyses were
performed using Graph Pad Prism software (Graph Pad Software, La Jolla,
CA, USA).
Further description for Bioinformatic analysis, tissue culture procedures, IHC and
skeletal staining, FACS, qRT-PCR, primer table, specific antibody usage, transplant
protocol and western blotting details please see Supplementary Data.
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